Journal of Infectious Diseases & Therapy
Open Access

Abstract

Background: Neonatal sepsis represents a diagnostic burden problem by showing minimal initial nonspecific manifestations.
The clinical course can be fulminate and fatal if treatment is not commenced promptly. It is therefore crucial to establish early
diagnosis and initiate adequate therapy. Blood culture takes up to 7 days for results and may be inconclusive, thus there is an
urgent need for a specific accurate marker for early diagnosis. The challenge of biomarker identification is reflected by the fact
that over 3000 sepsis biomarker studies last years. Neutrophil CD64, CD11b, monocyte CD14 and presepsin showed particular
promise in this aspect.
Aims: In this study we assessed the utility of all mentioned markers as an early predictive and monitoring marker and the best
panel of markers that can achieve the highest diagnostic performance in this disease.
Methods: Our study conducted over 9-months and included a total of 84 sepsis evaluations, neonates classified into three
groups: Documented sepsis group, Clinical sepsis group and Control group. Blood samples were collected for hs-CRP, CBC,
nCD64, nCD11b, m CD14, presepsin and blood culture.
Results: A statistically significant difference in levels of nCD64, presepsin and mCD14 was found in sepsis groups than in
control group; however nCD64 achieves the highest diagnostic performance than the other biomarkers. Combination of 2
markers achieves the highest diagnostic and prognostic performance over a single hematological parameter.
Conclusions: We can conclude that nCD64% represent the best early predictor and monitoring marker that can be incorporated
in the routine daily work in NICU.

Biography